Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- AmgenTEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTSCompanies: AmgenStatistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE THOUSAND OAKS, Calif., Aug. 27, 2026 -- Amgen...
- A decade of profitability provides foundation for CLINUVEL’s U.S. expansionCLINUVEL PHARMACEUTICALS LTD announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026).
- MindMaze Therapeutics Holding SAMindMaze Therapeutics Reports 2026 Half-Year Results and Corporate UpdateMindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in scalable precision neurotherapeutics, today announced the publication of its 2026 half-year report and provided a corporate update. Key Highlights...
- Jazz Pharmaceuticals plcJazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesJazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I...
- Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue GrowthResults Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 27, 2026 -- On August 26, 2026, Viva Biotech...
- Biosidus erweitert seine Produktionskapazitäten für Biologika und stärkt seine weltweiten Lieferkapazitäten für Agalsidase betaBUENOS AIRES, Argentinien, 27. August 2026 -- Biosidus, ein argentinisches Biotechnologieunternehmen mit mehr als vier Jahrzehnten Erfahrung in der Entwicklung und Herstellung von Biosimilar-Arzneimitteln, gab bekannt, dass seine neue Bioreaktor-Anlage nun in Betrieb genommen...
- Kahn Swick & Foti, LLCCapricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26,...
- The Rosen Law Firm PAROSEN, A LEADING NATIONAL FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- The Rosen Law Firm PAROSEN, LEADING INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class...
- AurekaNature Biotechnology | Aureka Wins the Global Blinded AI Antibody Benchmark: AI Design Surpasses the Best Experimental ResultThe complete results of AIntibody, the first international AI antibody design competition, have now been formally published in Nature Biotechnology. Widely regarded as the field's most rigorous test — every entry validated...
- EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudThe law firm of Kirby McInerney LLP is investigating potential claims against EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired EyePoint securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.
- ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc.The law firm of Kirby McInerney LLP continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.